U.S., Feb. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07400588) titled 'Aleniglipron Phase 2 in Type 2 Diabetes Mellitus' on Oct. 28, 2025.
Brief Summary: The purpose of this study is to assess the safety and tolerability of aleniglipron at doses up to 240 mg once daily (QD) in participants with T2DM who are living with obesity (body mass index [BMI] >= 30 kg/m2) or overweight (BMI >= 27 kg/m2).
Study Start Date: Dec. 01, 2025
Study Type: INTERVENTIONAL
Condition:
Obese
Obesity
Obesity Type 2 Diabetes Mellitus
Weight Loss
Intervention:
DRUG: Aleniglipron
Drug aleniglipron administered orally
DRUG: Placebo
Drug placebo administered orally
Recruitment Status: RECRUITING
Sponsor: Gasherbrum Bio,...